Natriumfusidat “essential Pharma (M)” (Fusidic Acid)

Fusidic acid binds to the bacterial elongation factor G (EF‑G) on the ribosome, preventing its release after peptide chain elongation. This blocks the translocation step of protein synthesis, halting bacterial protein production and producing a bacteriostatic effect against susceptible Gram‑positive organisms.

The dosage and infusion rate of Natriumfusidat “essential Pharma (M)” are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local guidelines. No fixed dose is provided here; the prescriber sets the appropriate regimen.

Safety data for fusidic acid in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Fusidic acid offers a unique mechanism by targeting EF‑G, which differs from beta‑lactams, glycopeptides (e.g., vancomycin) or lincosamides (e.g., clindamycin). It is particularly useful when organisms are resistant to other classes or when a bacteriostatic agent is preferred. However, its spectrum is limited mainly to Gram‑positive cocci, and clinicians must consider local susceptibility patterns when selecting therapy.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vials in the original packaging until use to maintain stability. If the solution appears cloudy or contains particles, discard it and use a new vial.

Natriumfusidat “essential Pharma (M)” is given as an intravenous infusion. The prescribed dose is diluted in an appropriate compatible IV fluid and administered over the period recommended by the treating physician, typically under aseptic conditions in a clinical setting.

The most serious adverse reactions include anaphylaxis, severe hepatic dysfunction (marked elevation of liver enzymes or jaundice), and severe cutaneous reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Prompt recognition and discontinuation of therapy are essential if any of these events occur.

Patients with a known hypersensitivity to fusidic acid or any component of the formulation should avoid the product. It is also contraindicated in individuals with severe hepatic impairment or those in whom the risk of serious allergic reactions outweighs potential benefits. Clinicians should evaluate each patient’s medical history before prescribing.